Genomtec S.A. Logo

Genomtec S.A.

Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.

GMT | WAR

Overview

Corporate Details

ISIN(s):
PLGNMTC00017
LEI:
259400ND13Y44ADMG554
Country:
Poland
Address:
WROCŁAW BIERUTOWSKA 57-59, 51-317 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genomtec S.A. is a medical technology company specializing in the research, development, and commercialization of innovative molecular diagnostic solutions. The company's flagship product is the Genomtec ID, a mobile platform designed for rapid and precise genetic diagnostics at the point-of-care. Its core technology is based on proprietary isothermal nucleic acid amplification methods. A key commercialized product is the CE-IVD certified GenomtecID Respiratory Panel 5-Plex, which detects viruses and bacteria responsible for respiratory tract infections. The company is also advancing its OncoSNAAT project in the field of genomics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 16:44
Regulatory News Service
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.4 KB
2025-09-29 18:10
Audit Report / Information
zal04_opinia_RN_do_stanowiska.pdf
Polish 154.5 KB
2025-09-29 18:10
Audit Report / Information
zal05_Stanowisko_Zarzadu_do_zastrzezenia.pdf
Polish 144.6 KB
2025-09-29 18:10
Management Discussion and Analysis
zal03_genomtec_sprawozdanie_zarzadu_ip_2025_vfinal_signed_1.pdf
Polish 1.1 MB
2025-09-29 18:10
Audit Report / Information
zal02_GENOMTEC_PSF_2025_MSR_Raport_z_przegladu_ost.pdf
Polish 420.3 KB
2025-09-29 18:10
Interim Report
zal01_genomtec_sf_06.2025_sig_signed.pdf
Polish 1.6 MB
2025-09-25 17:13
Regulatory News Service
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.6 KB
2025-09-15 17:12
Regulatory News Service
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 2.0 KB
2025-09-15 17:08
Share Issue/Capital Change
Podjęcie przez Zarząd Giełdy Papierów Wartościowych uchwały w sprawie dopuszcze…
Polish 1.0 KB
2025-09-11 17:57
Share Issue/Capital Change
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowegoPrzyznan…
Polish 2.3 KB
2025-08-14 17:28
Share Issue/Capital Change
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowego - Conte…
Polish 2.2 KB
2025-08-01 15:26
Regulatory News Service
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 1.7 KB
2025-07-31 10:13
Board/Management Information
Powołanie nowego Członka Zarządu GENOMTEC S.A. - Content (PL)
Polish 2.7 KB
2025-07-11 20:04
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym…
Polish 1.0 KB
2025-07-11 20:00
Post-Annual General Meeting Information
zal01_GENOMTEC_ESPI_32_2025_Zalacznik..pdf
Polish 129.4 KB

Automate Your Workflow. Get a real-time feed of all Genomtec S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genomtec S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genomtec S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland ORNAV
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea 222110
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea 304840

Talk to a Data Expert

Have a question? We'll get back to you promptly.